Logo

Moderna Reports First Patient Dosing in P-I Study of its HIV Trimer mRNA Vaccine

Share this

Moderna Reports First Patient Dosing in P-I Study of its HIV Trimer mRNA Vaccine

Shots:

  • The P-I study (HVTN 302) evaluates the safety and immunogenicity of investigational HIV trimer mRNA vaccines (mRNA-1574). The trial is expected to enroll ~100 HIV-negative adults, aged 18-55yrs.
  • The primary hypothesis is that the soluble & membrane-bound HIV envelope trimer mRNA vaccines will be safe and well-tolerated by HIV-uninfected individuals and will elicit autologous neutralizing Abs
  • Additionally, Moderna is partnering in the testing of HIV vaccine antigens mRNA-1644 and mRNA-1644v2-Core, being assessed in a P-I trial sponsored by IAVI and supported by the Bill & Melinda Gates Foundation

Ref: PR inside | Image: Moderna

Click here to­ read the full press release 

Senior Editor

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions